Journal: The Journal of Liquid Biopsy

Article Title: Novel applications of liquid Biopsy: Comprehensive methodology for circulating biomarker exploration in peripheral blood

doi: 10.1016/j.jlb.2025.100307

Figure Lengend Snippet: (A) Representative immunofluorescence images of CTCs with different extraction methods. Co-localization of STING (green, Alexa Fluor 488) and vimentin (red, Alexa Fluor 647). Nuclei were stained with DAPI (blue). Magnification 63X. (B) Representative SEM images of the isolated exosomes (scale bar = 2 μm). (C) Western blot of exosomal markers CD81 and CD63. The isolated exosomes with different protein concentrations (EXO#1 = 40 μg and EXO#2 = 20 μg) were successfully obtained from the culture supernatants of PBMCs from SCLC patients. Red line indicated the band of each protein on the gel. Original western blots are presented in File S1. (D) Stacked bar plots showing the log10-transformed positive control read counts across the samples. (E) Violin plot displaying the distribution of the log of the un-normalized gene counts for all the samples.

Article Snippet: MACS® Tumor Cell Isolation Kit depletes tumor-associated cells without harming CTCs; we modified the protocol by omitting Non-Tumor Cell Depletion Cocktail B to preserve mesenchymal CTCs (Order no. 130-108-339, www.miltenyibiotec.com ).

Techniques: Immunofluorescence, Extraction, Staining, Isolation, Western Blot, Transformation Assay, Positive Control

Journal: Cancer Cell International

Article Title: Redefining cancer care: harnessing circulating tumor cells’ potential for improved diagnosis and prognosis

doi: 10.1186/s12935-025-03883-y

Figure Lengend Snippet: Cancer specific CTC count as reported till date. Representative plot of range of circulating tumor cells (CTCs)/ 7.5 mL of peripheral blood as isolated from different cancer types. (Disclaimer: The figure represents an illustrative synthesis rather than directly comparable values. It reflects the broad range of reported CTC counts observed over a span of different clinical stages, CTC isolation techniques, detection platforms, and statistical approaches are tabulated in Supplementary Table ST1.)

Article Snippet: In one study, CTCs isolated from lung cancer patients using MetaCell technology proliferated in vitro with a success rate of 64.3% for functional characterization of CTCs [ ].

Techniques: Isolation

Journal: BMC Cancer

Article Title: Detecting androgen receptor (AR), AR variant 7 (AR-V7), prostate-specific membrane antigen (PSMA), and prostate-specific antigen (PSA) gene expression in CTCs and plasma exosome-derived cfRNA in patients with metastatic castration-resistant prostate cancer (mCRPC) by integrating the VTX-1 CTC isolation system with the QIAGEN AdnaTest

doi: 10.1186/s12885-024-12139-3

Figure Lengend Snippet: Workflow for AR, AR-V7, PSMA, and PSA AdnaTest applied to exosomal cfRNA and VTX-1-isolated CTCs. Blood was collected from patients with mCRPC and resistance to ARI inhibitors. Plasma was extracted from whole blood by centrifugation. ( A ) Exosomal cfRNA was extracted from plasma exosomes using exoRNeasy Serum Plasma Kit (QIAGEN). ( B ) CTCs were isolated from the plasma-depleted blood with VTX-1 and lysed using the Adna lysis/binding buffer. ( C ) CTC lysate and exosomal cfRNA were assayed for expression of AR, AR-V7, PSMA, and PSA mRNA with AdnaDetect. ( D ) A separate tube of whole blood was processed with VTX-1 in parallel for CTCs enumeration. mCRPC: metastatic castration-resistant prostate cancer; CTC: circulating tumor cell; mRNA: messenger RNA; AR: androgen receptor; AR-V7: AR splice variant 7; PSMA: prostate-specific membrane antigen; PSA: prostate-specific antigen; cfRNA: cell-free RNA

Article Snippet: In this study, we tested a workflow combining a CTC isolation step using the VTX-1 Liquid Biopsy System (Vortex Biosciences) with the AdnaTest ProstateCancerPanel AR-V7 (QIAGEN) to detect expression of wild-type AR, AR-V7, PSMA, and PSA in both CTCs and plasma exosomal cfRNA from patients with mCRPC and therapeutic resistance to ARIs.

Techniques: Isolation, Clinical Proteomics, Centrifugation, Lysis, Binding Assay, Expressing, Variant Assay, Membrane

Journal: BMC Cancer

Article Title: Detecting androgen receptor (AR), AR variant 7 (AR-V7), prostate-specific membrane antigen (PSMA), and prostate-specific antigen (PSA) gene expression in CTCs and plasma exosome-derived cfRNA in patients with metastatic castration-resistant prostate cancer (mCRPC) by integrating the VTX-1 CTC isolation system with the QIAGEN AdnaTest

doi: 10.1186/s12885-024-12139-3

Figure Lengend Snippet: Patient case studies. ( A ) Clinical course of patient #1 and timing of blood sampling over the course of his treatment. ( B ) Liquid biopsies and blood markers at two time points: PSA value, CTC numbers, AR-V7 results from both the VTX-1-AdnaDetect assay and the Oncotype DX AR-V7 Nucleus Detect test. ( C ) Side-by-side comparison of the AR-V7 results for three blood samples from 2 patients between the VTX-1-AdnaDetect assay and the Oncotype DX AR-V7 Nucleus Detect test. PC: prostate cancer; PSA: prostate-specific antigen; CTC: circulating tumor cell; AR-V7: androgen receptor splice variant 7; cfRNA: cell-free RNA.

Article Snippet: In this study, we tested a workflow combining a CTC isolation step using the VTX-1 Liquid Biopsy System (Vortex Biosciences) with the AdnaTest ProstateCancerPanel AR-V7 (QIAGEN) to detect expression of wild-type AR, AR-V7, PSMA, and PSA in both CTCs and plasma exosomal cfRNA from patients with mCRPC and therapeutic resistance to ARIs.

Techniques: Sampling, Comparison, Variant Assay